Drug Resistance Updates
Volume 12, Issue 6 , Pages 148-152, December 2009

Novel strategies for reversing platinum resistance

  • Mian M.K. Shahzad

      Affiliations

    • Department of Gynecologic Oncology, U.T.M.D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, United States
    • Department of Obstetrics and Gynecology, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, United States
    • ,
  • Gabriel Lopez-Berestein

      Affiliations

    • Department of Experimental Therapeutics, U.T.M.D. Anderson Cancer Center, 1155 Holcombe Blvd, Houston, TX 77030, United States
    • Department of Cancer Biology, U.T.M.D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, United States
    • Center for RNA Interference and Non-coding RNA, U.T.M.D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, United States
    • ,
  • Anil K. Sood

      Affiliations

    • Department of Gynecologic Oncology, U.T.M.D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, United States
    • Department of Cancer Biology, U.T.M.D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, United States
    • Center for RNA Interference and Non-coding RNA, U.T.M.D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, United States
    • Corresponding Author InformationCorresponding author at: Departments of Gynecologic Oncology and Cancer Biology, University of Texas M.D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, United States. Tel.: +1 713 745 5266; fax: +1 713 792 7586.

Received 31 August 2009; received in revised form 8 September 2009; accepted 9 September 2009. published online 06 October 2009.

Abstract 

Platinum-based drugs continue to be the mainstay of therapy for ovarian cancer. Along with adverse effects, chemoresistance (intrinsic or acquired) has become a major limitation in the management of recurrent disease. Even though much is known about the effects of platinum drugs on cancer cells, the mechanisms underlying resistance are poorly understood. In this review, we summarize the current data on chemoresistance and discuss novel strategies to reverse resistance to platinum-based drugs. The most important targets highlighted here include Aurora kinases, PARP, ATP7B, and ERCC1. Furthermore, we discuss the implications of these novel approaches for ovarian cancer treatment.

Keywords: ATP7B, Cisplatin, Chemoresistance, Drug transport, Kinases, MK-0457, Ovarian cancer, siRNA, Tumor stroma, BRCA1

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-7646(09)00050-8

doi:10.1016/j.drup.2009.09.001

Drug Resistance Updates
Volume 12, Issue 6 , Pages 148-152, December 2009

Article Tools

* Image Usage & Resolution